Cellular Principles Exam 3

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/93

encourage image

There's no tags or description

Looks like no tags are added yet.

94 Terms

1
New cards

process of target engagement to response

ligand-target interaction → molecular responses → cellular responses → disease modification

2
New cards

general receptor target interactions

agonists: increase activity

antagonists: decrease activity

3
New cards

general ion channels target interactions

blockers: decrease activity

modulators: can increase or decrease activity

4
New cards

general enzyme and transporter target interactions

inhibitor: decrease activity

substrate: increase activity

5
New cards

modifications made to corticosteroids to improve potency

  • double bond for stability

  • 9-F for mineralocorticoid activity

  • 11-OH group for activity

  • 21-OH for mineralocorticoid activity

  • 17-OH esterification for permeability

  • 16-OH for glucocorticoid activity (inhibits mineralocorticoid)

  • 3-keto for corticosteroid activity

  • 4-5 double bond for corticosteroid activity


6
New cards

ligand vs drug

ligands: endogenous compounds

drugs: exogenous compounds

7
New cards

estrogen receptor ligand vs drug example

ligand: estrogen/estradiol (agonist)

drug: raloxifene (antagonist)

8
New cards

examples of general estrogen receptors

nuclear receptors

  • ER alpha: reproductive tissues, bone density, breast cancer

  • ER beta: prostrate, ovaries, lungs, brain, immune system

membrane receptors

  • GPER1: triggers rapid, non-genomic signaling pathways


9
New cards

effect of radical DNA damage on ligand-target interactions

bases change conformation due to radicals, becoming their oxo form. 8-oxoA and 8-oxoG cause base-change mutations

10
New cards

Ka definition

association rate constant

Ka = [AB] / [A][B]

11
New cards

Kd definition

dissociation rate constant

Kd = [A][B] / [AB]

12
New cards

Ki definition

dissociation constant for enzyme inhibitors

Ki = [A][B] / [AB]

13
New cards

IC50 definition and equation

concentration of drug that blocks 50% of binding

IC50: Ki x (1 + [S]/Km)

14
New cards

Km definition

Michaelis constant: substrate concentration at half its maximum velocity of complex formation

Km = [S] at ½ Vmax

15
New cards

functions of different serotonin (5-HT) receptors

  • 5-HT1A: inhibits anxiety (agonists used)

  • 5-HT2A: increases anxiety (antagonists used)

  • 5-HT1B: inhibits aggression

  • 5-HT2B: regulates necessary cardiac function


16
New cards

effect of 5-HT1A agonists

increase the inhibition of anxiety and depression

17
New cards

effect of 5-HT2A antagonists

decrease the excitation of depression, migraines, schizophrenia

18
New cards

serotonin receptors definition

GPCRs that bind serotonin, epinephrine, norepinephrine, dopamine

19
New cards

serotonin (5-HT) synthesis process

L-tryptophan → oxidized → L-5-hydroxytryptophan → decarboxylated → 5-hydroxytryptophan (5-HT)

20
New cards

serotonin (5-HT) degradation process

catalyzed by monoamine oxidases (MAOs)

5-HT → oxidized → 5-HI acetic acid

5-HT → reduced → alcohol form

5-HT → acetylated → melatonin

21
New cards

MAOIs effect

inhibit serotonin degradation

22
New cards

selectivity equation

a + b → ab vs a + c → ac (b,c can be ligands or targets)

selectivity = pKiab - pKiac

higher pKi: more selective

23
New cards

dihydrofolate reductase (DHFR) definition/role

enzyme in thymidylate cycle that is a common drug target for cancer and infectious diseases; drugs made selective for pathogenic DHFR features

24
New cards

classes of enzymes and their definition

  • oxidoreductases: catalyze oxidation/reduction by transferring electrons & hydrogens

  • transferases: transfer functional groups between substrates

  • hydrolases: form two produces from a substrate via hydrolysis

  • lyases: non-hydrolytic addition or removal of groups from substrates

  • isomerases: intramolecular rearrangement

  • ligases: join together two molecules with ATP breakdown


25
New cards

cofactors definition and examples

metals necessary for some enzyme function

ex. Zn2+, Fe2+/3+, Cu+/2+, Mg2+

26
New cards

coenzymes definition and examples

organic molecules that bind to enzymes to help catalyze biochemical reactions

ex. NAD+/NADH, coenzyme A

27
New cards

apoenzyme vs holoenzyme

apoenzyme: inactive enzyme with no coenzyme

holoenzyme: active enzyme with coenzyme complex

28
New cards

activation energy definition

amount of energy needed to overcome transition state barrier

29
New cards

first step of Michaelis-Menten enzyme kinetics

association of enzyme and substate (E + S ←→ ES)

  • reversible step

  • forward rate constant: k1

  • reverse rate constant: k-1


30
New cards

second step of Michaelis-Menten enzyme kinetics

catalysis of substrate to product by enzyme (ES → E + P)

  • irreversible step

  • rate constant: k2


31
New cards

enzyme/substrate association and dissociation rate equations

association: ES = k1[E][S]

dissociation: E + S = k-1[ES]

32
New cards

enzyme product formation reaction rate equation

V0 = Vmax [S] / (Km + [S])

33
New cards

catalytic efficiency & kcat equations

catalytic efficiency = kcat/ Km

kcat = Vmax / [E]

34
New cards

substrate analog definition

chemical compound that resembles the substrate in an enzyme-catalyzed reaction

  • binds active site of enzyme to competitively inhibit enzyme


35
New cards

building blocks of nucleic acid

  • nucleobase: nitrogenous base

  • nucleoside: nitrogenous base + sugar

  • nucleotide: nitrogenous base + sugar + phosphate group(s)


36
New cards

anticancer nucleotide analog drugs

  • gemcitabine (cytidine analog)

  • 5-fluorouracil (uracil/thymine analog)

  • 6-thioguanine (guanine analog)


37
New cards

mechanism of action of 5-fluorouracil

covalently binds TS enzyme in thymidylate cycle to inactivate it; combined with oxaliplatin (cis-platin analog) for best results

38
New cards

mechanism of action of gemcitabine

inhibits replication in S phase

  • converted into triphosphate, incorporated into DNA to act as chain terminator

  • inhibits ribonucleotide reductase to inhibit DNA replication


39
New cards

cyclooxygenases

oxidoreductase enzymes involved in prostaglandin synthesis

  • COX-1: constituently expressed in most cells

  • COX-2: induced expression in macrophages during inflammation


40
New cards

common use of kinase inhibitor drugs

anticancer drugs (oncogenes are kinases and tumor suppressors are phosphatases)

41
New cards

types of kinase inhibitors

  • type I: ATP competitive; binds to adenine, sugar, and phosphate binding regions

  • type II: non-ATP competitive; binds to adenine and allosteric sites

    • imatinib: kinase inhibitor used for chronic myeloid leukemia

    • vemurafenib: kinase inhibitor used for late-stage melanoma


42
New cards

target of DNA alkylating agents

covalently bind to DNA at alkylation sites of major grooves (N3 on adenine or N7 on guanine), resulting in enol tautomer, which causes mutations

43
New cards

mutations caused by DNA alkylation

  • deletion of alkylated base (A or G)

  • mismatches from keto-enol tautomerization

  • strand brakes due to spontaneous depurination exposing AP sites vulnerable to cleavage

  • inability to replicate due to alkyl conjugations


44
New cards

DNA alkylation mechanism of action

nucleophilic atom on DNA attacks drug carbocation to form iminium ion, resulting in alkylation. This step is repeated to form a second alkylation, resulting in cross-links

45
New cards

examples of DNA alkylating agents

  • cisplatin: forms intrastrand cross-links from repeated alkylation covalent bonds

  • melphalan: forms interstrand cross-links from repeates alkylation covalent bonds


46
New cards

non-covalent ligand-DNA interactions

minor groove binders and intercalating agents, which form intermolecular forces with DNA

47
New cards

example of minor groove DNA binder

distamycin; binds AT rich regions with positively charged terminal amidine

48
New cards

examples of intercalating agents

daunomycin/doxorubicin and dynemicin A

49
New cards

daunomycin/doxorubicin class and effect

anthracycline antibiotic (four fused rings in a line) that intercalates into DNA major groove to inhibit topoisomerase progression in replication

50
New cards

dynemicin A class and effect

anthracycline (four linear fused rings) and enediyne (diene w/ two triple bonds) that intercalates into DNA minor groove to cleave strand(s)

51
New cards

antiviral nucleotide analog drugs

  • zidovudine (AZT): dehydroxylated (3’-OH) nucleoside to form azido group (prevents elongation)

  • adefovir: phosponated nucleotide (increase stability) w/ opened nucleoside (prevents elongation)


52
New cards

cellular responses to DNA damage

  • DNA damage repair: takes energy and resources, but fixes damage

  • DNA damage tolerance: continued replication deemed less damaging (translesion synthesis)


53
New cards

mRNA functions

  • transcription

  • intron removal (splicing)

  • non-miRNA regulates stability


54
New cards

splicing process

donor splice site at 5’ intron end and acceptor splice site at 3’ intron site cause separation of exons and introns

55
New cards

introns definition

untranslated regions (UTRs) of mRNA that contain miRNA information

56
New cards

role of miRNA regulation

gene silencing: inhibition of translation

57
New cards

methods of gene silencing by miRNAs

  • translation repression: prevent the mRNA from being translated into protein

  • RNA cleavage: destroy the mRNA


58
New cards

biogenesis process of miRNAs

  • drosha (nuclear RNase) cuts pri-miRNA into pre-miRNA

  • dicer enzyme processes hairpin pre-miRNA, and cuts it into ds miRNA

  • helicase: cuts ds miRNA into single strands

  • AGO (catalytic components of RISC) binds miRNA and siRNA to regulate gene expression


59
New cards

siRNA definition and role

synthetic miRNA (short, double stranded) that is used to knockdown specific target mRNAs (temporary gene silencing)

60
New cards

siRNA drug example

patisiran, which consists of a guide and passenger strand with dinucleotide overhangs. guide strand binds target mRNA

61
New cards

siRNA backbone modifications

modifications to improve stability

  • S added to phosphate group

  • 2’-O-methyl group

  • 2’-fluoro group

  • 2’-O-methoxyethyl group

modifications to improve delivery

  • LPS packaging

  • GalNAc conjugation


62
New cards

mechanisms of action of antisense oligonucleotides (ASOs)

  • steric blocking of mRNA splicing in nucleus (main mechanism)

  • steric blocking translation in cytoplasm (prevents ribosome association)

  • mRNA cleavage and destruction in cytoplasm by recruiting RNase H


63
New cards

mipomersen

ASO drug that targets mRNA encoding Apo B-100 for cleavage by RNase H to lower LDL

64
New cards

four major types of receptors

  • ion channel receptors for conductance

  • G protein coupled receptors for cell signaling

  • receptor tyrosine kinases for cell signaling

  • nuclear receptors for transcription and translation


65
New cards

signal transduction definition

extracellular ligands (first messenger) bind receptor to regulate intracellular processes using second messengers

66
New cards

general receptor actions

  • transducer: can pass along a signal, often via a new form

  • discriminator: selectively responds to some signals but not others

  • amplifier: increases magnitude of a response


67
New cards

affinity vs efficacy vs potency

  • affinity: ability of a ligand to bind a target

  • efficacy: ability of an activated receptor to initiate a response

  • potency: how much of a ligand is needed to produce effects


68
New cards

occupancy theory

number of receptor interactions impacts the magnitude of effect (not linear)

69
New cards

occupancy theory reaction

occupancy = [D] / ([D] + Kd)

fractional occupancy (when reaction is not complete): f = [LR] / ([R] + [LR])

70
New cards

rate theory

rate/frequency of ligand-receptor association and dissociation impacts the magnitude of effect

71
New cards

rate theory equation

Kd = koff / kon = k-1 / k1

72
New cards

general types/effects of ligands

  • agonist: ligand that binds a receptor to stimulate a response (efficacy α = 1)

  • partial agonist: small stimulus that results in small effect on response (0 < α < 1)

  • inverse agonist: ligand stimulates an opposite response to favor inactive receptor ( -1 < α < 0)

  • antagonist: ligand binds a receptor to prevent a response


73
New cards

types of antagonists

  • competitive: compete with agonist to decrease potency (no effect on efficacy)

  • irreversible: decreases potency and efficacy

  • physiological antagonism: two receptors have opposite effect on same second messenger


74
New cards

classes of second messengers

  • hydrophobic molecules: membrane associated (PIP3, DAG)

  • hydrophilic molecules: cytoplasm associated (cAMP, cGMP, IP3, Ca2+)

  • gases


75
New cards

adenylyl cyclase kinase cascade

  • adenylyl cyclase activated by receptor causes 3’-OH of ATP ring to attack α-P, resulting in cAMP

  • cAMP binds protein kinase A, inducing a conformation change

  • PKA becomes active, causing series of phosphorylation events, leading to activation of CRB transcription factor


76
New cards

receptor tyrosine kinases definition

receptors that dimerize to cause downstream sequence of phosphorylation events

77
New cards

growth factor receptors definition

receptor tyrosine kinases that lead to cell proliferation, gene expression, and cell migration

78
New cards

GFR mechanism of action

  • ligand binds to receptor’s extracellular domain (N-terminal), causing dimerization

  • intracellular catalytic domain (C-terminal) autophosphorylates tyrosine residue on other dimer

  • tyrosine kinase region activates and transfers phosphate from ATP to signaling protein


79
New cards

EGFR mechanism of action

MAPK cascade

  • ligands cause dimerization

  • active phosphorylated catalytic region has SH2 binding domains, which bind Grb2 protein

  • bound Grb2 protein phosphorylates Ras protein, initiation phosphorylation cascade

  • EGFR → Grb2 → Ras → MEK-PO4 → MAPK-PO4 → transcription factors


80
New cards

GFR families

  • epidermal growth factor receptors (EGFR/HER/ERB)

  • fibroblast growth factor receptors (FGFR)

  • vascular endothelial growth factor receptors (VEGFR)

  • insulin-like growth factor receptors (IGFR)


81
New cards

drugs that inhibit EGFR

biologic monoclonal antibodies that block ligand binding extracellular domain

  • cetuximab binds EGFR in cancer

  • bevacizumab binds VEGFR in cancer and macular degeneration

  • daclizumab binds IL2 in multiple sclerosis

  • trastuzumab binds HER2 in breast cancer

small molecules that block ATP binding on intracellular domain

  • geftinib

  • erlotinib (binds active EGFR after EGF binds)


82
New cards

VEGFR mechanism of action

IP3 signaling pathway

  • receptor dimerization increase phospholipase C activity, which elevates IP3 concentrations

  • IP3 stimulates release of Ca2+ from intracellular stores

  • Ca2+ stimulates phosphatase calcineurin, which dephosphorylates NFAT transcription factor

  • NFAT dephosphorylation activates it and translocates it to nucleus


83
New cards

drug that inhibits VEGFR

cyclosporine: immunosuppressant that inhibits phosphatase calcineurin from dephosphorylating NFAT

84
New cards

dose definitions

  • medical: amount of drug administered at a given time to achieve desired response

  • biochemical: amount of drug necessary to yield a desired concentration at the active site


85
New cards

endpoints used to measure drug response

  • measured parameter of a desired effect

    • physiological, biochemical, toxicological, behavioral

  • measurements of percent of a population (human/animal) affected

    • death, desired improvements, toxic effects


86
New cards

stages of drug-receptor interactions

  • drug binding to the receptor (affinity)

  • production of an effect (efficacy)


87
New cards

four important parameters of a dose response curve

  • threshold response: first drug concentration where there’s an effect

  • maximal response: more drug can’t increase effect

  • slope: amount of drug effect that a given drug concentration has

    • steep: small change in [drug] → major impact

    • shallow: large change in [drug] → subtle impact

  • EC50 (potency): drug concentration that gives 50% maximal response


88
New cards

how potency differences are shown on dose response curve

differences in EC50 (left shift = greater potency), but no change in Emax

  • potency not very important in choosing drug candidate


89
New cards

how efficacy differences are shown on dose response curve

differences in Emax (higher Emax = higher efficacy), but no change in EC 50

  • efficacy very important when choosing drug candidate


90
New cards

how types of antagonists are shown on dose response curves

competitive on left, irreversible on right

<p>competitive on left, irreversible on right</p>
91
New cards

how types of agonists are shown on dose response curves

knowt flashcard image
92
New cards

parameters of population dose response curves

ED50: dose at which 50% of population reaches therapeutic endpoint

TD50: dose at which 50% of population reaches toxic endpoint

LD50: dose at which 50% of population dies

<p>ED<sub>50</sub>: dose at which 50% of population reaches therapeutic endpoint</p><p>TD<sub>50</sub>: dose at which 50% of population reaches toxic endpoint</p><p>LD<sub>50</sub>: dose at which 50% of population dies</p>
93
New cards

therapeutic index

TD50 / ED50 or LD50 / ED50

higher therapeutic index = wider therapeutic window = safer drug

94
New cards

types of population dose response curves

  • symmetric histogram: standard curve from continuous endpoint, which mean in the middle of a bell curve

  • skewed histogram: asymmetric bell curve with outlier populations that required varied dosing due to other factors

  • bimodal histogram: two peaks present due to different results in different subpopulations